Avalon Pharmaceuticals: AVN944 (IMPDH Inhibitor) and Beta-catenin Inhibitor Programs to be Presented at the American Society of Hematology Meeting

GERMANTOWN, Md.--(BUSINESS WIRE)--Avalon Pharmaceuticals, Inc. (Nasdaq:AVRX), today announced that two posters will be presented at the American Society of Hematology (ASH) Annual Meeting, December 7-11, 2007, in Atlanta, GA.